221 related articles for article (PubMed ID: 25313368)
1. Ramucirumab and its use in gastric cancer treatment.
Bronte G; Galvano A; Cicero G; Passiglia F; Rolfo C; Bazan V; Russo A
Drugs Today (Barc); 2014 Sep; 50(9):613-21. PubMed ID: 25313368
[TBL] [Abstract][Full Text] [Related]
2. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.
Fuchs CS; Tomasek J; Yong CJ; Dumitru F; Passalacqua R; Goswami C; Safran H; Dos Santos LV; Aprile G; Ferry DR; Melichar B; Tehfe M; Topuzov E; Zalcberg JR; Chau I; Campbell W; Sivanandan C; Pikiel J; Koshiji M; Hsu Y; Liepa AM; Gao L; Schwartz JD; Tabernero J;
Lancet; 2014 Jan; 383(9911):31-39. PubMed ID: 24094768
[TBL] [Abstract][Full Text] [Related]
3. Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab.
Fuchs CS; Tabernero J; Tomášek J; Chau I; Melichar B; Safran H; Tehfe MA; Filip D; Topuzov E; Schlittler L; Udrea AA; Campbell W; Brincat S; Emig M; Melemed SA; Hozak RR; Ferry D; Caldwell CW; Ajani JA
Br J Cancer; 2016 Oct; 115(8):974-982. PubMed ID: 27623234
[TBL] [Abstract][Full Text] [Related]
4. Ramucirumab for gastric cancer.
Shitara K; Ohtsu A
Expert Rev Gastroenterol Hepatol; 2015 Feb; 9(2):133-9. PubMed ID: 25431958
[TBL] [Abstract][Full Text] [Related]
5. Ramucirumab: successfully targeting angiogenesis in gastric cancer.
Javle M; Smyth EC; Chau I
Clin Cancer Res; 2014 Dec; 20(23):5875-81. PubMed ID: 25281695
[TBL] [Abstract][Full Text] [Related]
6. Ramucirumab for the treatment of gastric cancers, colorectal adenocarcinomas, and other gastrointestinal malignancies.
Aprile G; Ferrari L; Cremolini C; Bergamo F; Fontanella C; Battaglin F; Rihawi K; Lonardi S; Loupakis F; Scartozzi M
Expert Rev Clin Pharmacol; 2016 Jul; 9(7):877-85. PubMed ID: 27149032
[TBL] [Abstract][Full Text] [Related]
7. Ramucirumab and its use in the treatment of hepatocellular carcinoma.
Turkes F; Chau I
Future Oncol; 2019 Mar; 15(9):979-988. PubMed ID: 30644314
[TBL] [Abstract][Full Text] [Related]
8. Ramucirumab: first global approval.
Poole RM; Vaidya A
Drugs; 2014 Jun; 74(9):1047-58. PubMed ID: 24916147
[TBL] [Abstract][Full Text] [Related]
9. [Ramucirumab - a new anticancer agent].
Telekes A; Deme D
Orv Hetil; 2016 Oct; 157(40):1587-1594. PubMed ID: 27690622
[TBL] [Abstract][Full Text] [Related]
10. Ramucirumab for metastatic gastric or gastroesophageal junction cancer: results and implications of the REGARD trial.
Liguigli W; Tomasello G; Toppo L; Ratti M; Passalacqua R
Future Oncol; 2014; 10(9):1549-57. PubMed ID: 25145426
[TBL] [Abstract][Full Text] [Related]
11. Targeted inhibition of VEGF receptor 2: an update on ramucirumab.
Clarke JM; Hurwitz HI
Expert Opin Biol Ther; 2013 Aug; 13(8):1187-96. PubMed ID: 23803182
[TBL] [Abstract][Full Text] [Related]
12. Ramucirumab (IMC-1121B): Monoclonal antibody inhibition of vascular endothelial growth factor receptor-2.
Spratlin J
Curr Oncol Rep; 2011 Apr; 13(2):97-102. PubMed ID: 21222245
[TBL] [Abstract][Full Text] [Related]
13. Tanibirumab (TTAC-0001): a fully human monoclonal antibody targets vascular endothelial growth factor receptor 2 (VEGFR-2).
Lee SH
Arch Pharm Res; 2011 Aug; 34(8):1223-6. PubMed ID: 21910042
[TBL] [Abstract][Full Text] [Related]
14. Ramucirumab: targeting angiogenesis in the treatment of gastric cancer.
Smyth EC; Tarazona N; Chau I
Immunotherapy; 2014; 6(11):1177-86. PubMed ID: 25496333
[TBL] [Abstract][Full Text] [Related]
15. Gastric Carcinoma at the Era of Targeted Therapies.
Dreanic J; Dhooge M; Sion E; Brezault C; Chaussade S; Coriat R
Curr Drug Targets; 2016; 17(15):1818-1826. PubMed ID: 25944013
[TBL] [Abstract][Full Text] [Related]
16. Targeting VEGFR-2 in Metastatic Gastric Cancer: Results From a Literature-Based Meta-Analysis.
Roviello G; Polom K; Roviello F; Marrelli D; Multari AG; Paganini G; Pacifico C; Generali D
Cancer Invest; 2017 Mar; 35(3):187-194. PubMed ID: 28165839
[TBL] [Abstract][Full Text] [Related]
17. Ramucirumab: A Review in Advanced Gastric Cancer.
Greig SL; Keating GM
BioDrugs; 2015 Oct; 29(5):341-51. PubMed ID: 26341713
[TBL] [Abstract][Full Text] [Related]
18. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.
Spratlin JL; Cohen RB; Eadens M; Gore L; Camidge DR; Diab S; Leong S; O'Bryant C; Chow LQ; Serkova NJ; Meropol NJ; Lewis NL; Chiorean EG; Fox F; Youssoufian H; Rowinsky EK; Eckhardt SG
J Clin Oncol; 2010 Feb; 28(5):780-7. PubMed ID: 20048182
[TBL] [Abstract][Full Text] [Related]
19. Ramucirumab, a fully human mAb to the transmembrane signaling tyrosine kinase VEGFR-2 for the potential treatment of cancer.
Krupitskaya Y; Wakelee HA
Curr Opin Investig Drugs; 2009 Jun; 10(6):597-605. PubMed ID: 19513949
[TBL] [Abstract][Full Text] [Related]
20. Ramucirumab: A vascular endothelial growth factor receptor-2 inhibitor with activity in several malignancies.
Grabowski J; Glode A
Am J Health Syst Pharm; 2016 Jul; 73(13):957-68. PubMed ID: 27217518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
